Functional Brands Inc. Announces Launch of GLP-Squared Injection

Proprietary Semaglutide + Tirzepatide Dual-Peptide Formulation Now Available Exclusively Through the Tru2u.health Platform Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a pioneer in next-generation health and wellness solutions, today announced the official launch of GLP-Squared Injection, its groundbreaking dual-peptide injectable combining Semaglutide and Tirzepatide in a single, synergistic formulation. GLP-Squared is now exclusively available to members of the Company's flagship digital health platform, Tru2u.health.